Puede ser elegible para un estudio clínico de un nuevo medicamento que puede prevenir la infección de COVID-19.
Los participantes inscritos recibirán un pago por cada visita de estudio.
Llene la forma y nosotros nos comunicaremos con usted.
Ruane Clinical Research is a dedicated and diverse team of physicians and allied health professionals with expertise in the treatment of HIV, hepatitis B, hepatitis C, Nonalcoholic Steatohepatitis (NASH) and HIV prevention (PrEP). Studying the newest therapies available from the leading international bio-pharmaceutical companies, we have conducted 176 clinical trials since 2006. Dr. Peter Ruane is a board-certified Infectious Disease and Internal Medicine physician. Dr. Ruane first engaged in clinical research in 1995 at the height of the AIDS crisis with the advent of protease inhibitor therapy. He has since been a principal investigator for every HIV drug marketed since 1997. He has witnessed the importance of bringing new therapies expeditiously to patients.